Director/PDMR Shareholding
Summary by AI BETAClose X
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Luke Miels |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£21.68 |
24,979.493 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-10 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Regis Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £270,777.70 less applicable tax withholding in respect of 12,489.746 notional Ordinary Shares. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£21.68 |
12,489.746 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-10 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Deborah Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£21.68 |
24,979.493 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-10 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 days ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund